Scientists find key to regenerating blood vessels
Lake Nona, Fla., November 23, 2017 – A new study led by researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP) identifies a signaling pathway that is essential for angiogenesis, the growth of new blood vessels from pre-existing vessels. The findings, published in Nature Communications, may improve current strategies to improve blood flow in ischemic tissue, such as that found in atherosclerosis and peripheral vascular disease associated with diabetes.
“Our research shows that the formation of fully functional blood vessels requires activation of protein kinase Akt by a protein called R-Ras, and this mechanism is necessary for the formation of the hallow structure, or lumen, of a blood vessel.” says Masanobu Komatsu, Ph.D., associate professor at SBP’s Lake Nona campus. “The findings are important because they shed new light on the biological process needed to increase blood flow in ischemic tissues.”
Previous efforts to treat ischemia by creating new blood vessels have focused on delivering angiogenic growth factors like vascular endothelial growth factor (VEGF) to ischemic sites. But all of these studies, including more than 25 phase II and III clinical trials, have failed to offer significant benefit to patients.
Komatsu’s research team used a combination of 3D cell culture and living tissue to show that VEGF promotes vascularization, but the vessel structures formed are chaotic, unstable and non-functional. “Functional vessels need to have a lumen; a pipe-like opening that allows oxygenated blood and nutrients to travel through the body,” explains Komatsu, “and VEGF alone cannot fully support the formation of such a vessel structure.”
“Generating new blood vessels is similar to the way trees grow; sprouts develop from existing vessels and then branch out further and further to restore vascularity, says Fangfei Li, Ph.D., postdoctoral associate in Komatsu’s lab and lead author of the paper. “This study shows that there are distinct steps and signals that control the process.
“First, VEGF activates Akt to induce endothelial cells to sprout. Then, R-Ras activates Akt to induce lumen formation,” explains Li. “The second step involving Akt activation by R-Ras stabilizes the microtubule cytoskeleton in endothelial cells, creating a steady architecture that promotes lumen formation,” explains Li.
“We propose that VEGF and R-Ras activation of Akt signaling are complementary to each other, both are necessary to generate fully functional blood vessels to repair ischemic tissue,” says Komatsu. “Our next step is to work toward promoting the combined signaling of Akt in clinical studies; prompting R-Ras activation through either gene therapy or pharmacologically in parallel with VEGF therapy,” says Komatsu.
Junko Sawada, a staff scientist in the Komatsu lab, was a co-author of this study.
Funding sources for this research came, in part, from the National Cancer Institute (CA125255), the National Science Foundation Grant (CBET-1403535), the American Heart Association, the Bankhead-Coley Cancer Research Program (4BB17), and the Florida Breast Cancer Foundation.
Sanford Burnham Prebys Medical Discovery Institute (SBP) is an independent nonprofit medical research organization that conducts world-class, collaborative, biological research and translates its discoveries for the benefit of patients. SBP focuses its research on cancer, immunity, neurodegeneration, metabolic disorders and rare children’s diseases. The Institute invests in talent, technology and partnerships to accelerate the translation of laboratory discoveries that will have the greatest impact on patients. Recognized for its world-class NCI-designated Cancer Center and the Conrad Prebys Center for Chemical Genomics, SBP employs about 1,100 scientists and staff in San Diego (La Jolla), Calif., and Orlando (Lake Nona), Fla. For more information, visit us at SBPdiscovery.org or on Facebook at facebook.com/SBPdiscovery and on Twitter @SBPdiscovery.